Olfactory Training for Olfactory Dysfunction After Coronavirus Disease - 19 (COVID-19)

NCT04764981 | Unknown

• 1 other identifier: OLFATO001
• Study Type: interventional
• Target: 350
• Locations: 1 country
• Sites: 1

Brief Summary

It is a randomized controlled clinical trial study that aims to follow a sample of individuals with persistent olfactory dysfunction post-COVID-19. The aim of this study is assess the clinical outcomes of olfactory training therapy in the treatment of persistent olfactory dysfunctions after COVID-19. The sample will consist of 350 participants, being 300 individuals with persistent olfactory dysfunction post-COVID-19 and 50 healthy individuals. Volunteers' will be separated in two experimental groups (1 and 2 ) and a control group. All participants will be submitted to clinical evaluation that include the Connecticut Chemosensory Clinical Research Test (CCCRT), an olfactory test to diagnose anosmia and hyposmia, and two skull Magnetic Resonance imaging (MRI). Only participants of Experimental group 1 will be submitted to an olfactory training with essences oils. Experimental group 2 will only receive a clinical follow-up after three months and control group will be only submitted to neurological exam, olfactory test, MRI imaging and test their ability to discriminate the essence oils used in olfactory training. As a result, is expected a better understanding of the characteristics of olfactory dysfunction caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) virus infection, as well as the effectiveness and viability of using Olfactory Training as a therapeutic alternative.

Conditions

Covid19; SARS-CoV Infection; Olfactory Disorder; Anosmia

Outcome Measures

Primary Outcomes (1)

• To Assess the effectiveness of olfactory training therapy in the treatment of persistent olfactory dysfunctions after COVID-19

  The individuals of Experimental group 1 will be submitted to a olfactory training with essence oils, the participants will be reassessed with Olfactory test CCCRT monthly and this results will be compared with the reassessment results of the Experimental group 2 (no intervention group). The results of CCCRT of these two groups will be compared with Control group. The CCCRT olfactory test consists of n-butanol smell threshold test and smell identification test. Olfactory function score will be assessed (0: worst score; 7: best score).

  4 years

Secondary Outcomes (3)

• To Investigate by means of skull nuclear magnetic resonance (MRI) exams for possible neural correlates of olfactory dysfunctions present in post-COVID-19 patients

  4 years

• To Measure by means of a standardized olfactory test the olfactory dysfunctions present in post-COVID-19 patients

  4 years

• Propose an olfactory training protocol appropriate to the demands of patients with post-COVID-19 olfactory dysfunction and in accordance with the reality of Brazilian public health services

  4 years

Study Arms (3)

Experimental Group 1: Essences Oils

EXPERIMENTAL

The individuals of this group are 150 individuals with olfactory disorder related to COVID-19 that will be submitted to clinical exams, olfactory test and MRI imaging, after that, participants will undergo an olfactory training with essences oils. Each participant in this group will receive a kit with four 30 ml bottles, each containing a circular piece of watercolor paper soaked in one of the four essences oils (rose, eucalyptus, lemon and cloves) used in olfactory training, a manual to make the olfactory training at home and a self-assessment diary which should be filled weekly. Each participant of this group will use the training kit for three months, the olfactory training consists of inhaling each of the substances for 30 seconds, with an interval of 30 seconds between them, twice a day, upon waking up and before bed, the participants will be reassessed with CCCRT after each month of training. The results of this group will be compared with the other groups.

Other: Essence oils

Experimental Group 2: Clinical follow-up

NO INTERVENTION

The individuals of this group are 150 individuals with olfactory disorder related to COVID-19. that will be submitted to clinical exams, olfactory test and MRI imaging, after three months they will be reassessed.

Control Group

NO INTERVENTION

The individuals of this group are 50 healthy individuals, without previous COVID-19 infection, that will be submitted to clinical exams, olfactory test, MRI imaging and the participants will be tested for the ability to identification of the essence oils utilized by Experimental group 1.

Interventions

Essence oils OTHER

Consists in olfactory training using essence oils

Experimental Group 1: Essences Oils

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Confirmed diagnosis of COVID-19 by Real Time Polymerase chain-reaction for SARS-CoV-2 or serological tests for SARS-CoV-2 antigens.\\
• Olfactory dysfunction confirmed by Connecticut Chemosensory Clinical Research Test (CCCRC-T).

You may not qualify if:

• Smokers
• Individuals with diagnosed rhinitis
• Individuals with diagnosed Neurological diseases
• Individuals submitted to brain surgery
• Previous historic of hyposmia and/ or anosmia
• Pregnancy
• Allergy to any of the substances present in the olfactory test kit
• Individuals who are undergoing another treatment for olfactory dysfunction

Sponsors & Collaborators

• Universidade do Estado do Pará: lead

Study Sites (1)

Unidade de Ensino E Assistência Em Fisioterapia E Terapia Ocupacional

Belém, Pará, 66095-661, Brazil

Location

MeSH Terms

Conditions

COVID-19; Severe Acute Respiratory Syndrome; Anosmia

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Olfaction Disorders; Sensation Disorders; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Masking Details: Participants of groups will be evaluated and random inserted in one of the experimental groups. The person responsible for reassessment will be blinded for which group the individual reassessed came from.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: Randomized controlled clinical trial study, with 2 experimental groups

Study Record Dates

• First Submitted: February 14, 2021
• First Posted: February 21, 2021
• Study Start: May 1, 2021
• Primary Completion: May 1, 2022
• Study Completion: May 1, 2024
• Last Updated: February 21, 2021

Record last verified: 2021-02

Locations

BR (1)